Andrew Smith, Chief Operations and Innovation Officer at Vituity and President of Inflect Health discusses the launch of Healthful, one of the first proprietary patient navigation platforms that leverage AI and machine learning to accurately and proactively identify patients who will benefit most from high touch care navigation. He talks about the benefits of Healthful’s approach to patient navigation to produce a holistic healthcare journey; addressing variables like transportation and scheduling that impact patients’ access to care.
INTERVIEWS
Perspectives From a Leading Alzheimer’s Disease Researcher
Dr. David Henley, MD, Executive Medical Director, Alzheimer’s Disease Global Medical Affairs, Neurology Business Group at Eisai Inc. shares his perspective on recent advances in Alzheimer’s Disease research and therapeutic approaches including the role of the amyloid-beta pathway.
Diabetes Patient Success Story – Managing Your Diagnosis Through Collaborative Treatment and Proper Diet
In this segment, Ms. Jean Ford a 78-year-old diabetic and cancer survivor discusses the challenges she faced from her type-II diabetes as well as the treatment plan and education she received from the doctors at Weill Cornell Medicine that enabled her to live a medication-free lifestyle.
New Book Reveals the Secrets to Male Health and Wellbeing
Dr. Judson Brandeis, MD, urologist, and sexual medicine expert discusses his new book, “The 21st Century Man: Advice from 50 Top Doctors and Men’s Health Experts to Help You Feel Great, Look Good and Have Better Sex”.
Janssen Reports Positive Phase 3 TREMFYA Data in Patients with Difficult-to-Treat PsA
Dr. Soumya Chakravarty, MD, Ph.D., Senior Director & Strategic Lead, Rheumatology Therapeutic Area, U.S. Immunology Medical Affairs, Janssen Scientific Affairs, discusses the latest Phase 3 TREMFYA (guselkumab) data that was published in the “Annals of the Rheumatic Diseases” which demonstrated improvements in joint and skin symptoms in patients with difficult-to-treat psoriatic arthritis (PsA). The study results also show TREMFYA provided greater improvements in physical function and health-related quality of life scores compared to placebo. COSMOS is the first study to evaluate the safety and efficacy of an IL-23 inhibitor therapy in adults with active PsA and an inadequate response to tumor necrosis factor inhibition.
New Data from GRITT™ (Gaining Resilience Through Transitions) Program for IBD Patients
Returning guest, Dr. Laurie Keefer, PhD, GI Health Psychologist and Professor of Medicine and Psychiatry at the Icahn School of Medicine at Mount Sinai in NYC discusses new data from GRITT™ (Gaining Resilience Through Transitions) Program that was published in “Clinical Gastroenterology and Hepatology” (Nov 15, 2021) which showed that inflammatory bowel disease (IBD) patients with high resilience saw dramatic reductions in unplanned healthcare, opioid, and steroid use. The GRITT™ method simultaneously addresses mind AND body targets in patients with IBD and continues to show improvements in disease management in IBD patients. The implications for patient care are that psychological resilience could be an earlier, more inclusive target for intervention as part of true mind-body care in IBD.
Outset Medical – Tablo Hemodialysis System
Dr. Michael Aragon, Chief Medical Officer of Outset Medical based in San Jose, California, discusses how the company is reducing the cost and complexity of dialysis with its first-of-its-kind technology, the Tablo Hemodialysis System. Tablo, which is FDA cleared for use from the hospital to home, combines consumer product simplicity and real-time water purification into a compact unit that delivers dialysis with sophisticated simplicity. He also discusses Outset’s continued momentum in the acute market, patient adoption, and early home success.
Blackrock Neurotech – MoveAgain Brain-Computer Interface System
Professor Florian Solzbacher, Co-Founder, Chairman, and President of Blackrock Neurotech discusses the MoveAgain Brain-Computer Interface (BCI) System that the FDA has granted a Breakthrough Device designation. It utilizes an array (electrode) implanted in the brain, which decodes intended movement from neuronal activity in the brain. This game-changing portable BCI offers patients new possibilities for movement and independence, reducing their reliance on caregivers and helping them better engage with society and the world. Blackrock has been leading the market for BCI technology for 15 years, with more humans implanted with Blackrock technology than any other BCI platform. Their aim is to commercially release the MoveAgain BCI system in 2022.
ACR 2021 New UCB Data Across Rheumatology Clinical Programs
Returning guest, Dr. Jeff Stark, MD, Head of US Medical Immunology at UCB discusses new data presented at the American College of Rheumatology (ACR) Convergence 2021 virtual congress on bimekizumab, UCB’s investigational IL-17A and IL-17F inhibitor from the Phase 2b BE AGILE study and its open-label extension data in ankylosing spondylitis (AS), and CIMZIA ® (certolizumab pegol), a TNF inhibitor, pivotal Phase 3 study evaluating the long-term safety and efficacy of CIMZIA in non-radiographic axial spondyloarthritis (nr-axSpA).
Diabetes Awareness – Endocrinologist and Registered Dietician
In this segment, Dr. Gwendolyne Jack, endocrinologist and Assistant Professor of Clinical Medicine at Weill Cornell Medicine, and Rachel Stahl, Registered Dietician and Education Specialist in the Division of Endocrinology, Diabetes and Metabolism at Weill Cornell Medicine discuss their approach to treating diabetic patients and the success that they have had.